Compare BridgeBio Pharma Inc (BBIO) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Home Depot Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Home Depot Inc trades at $354.05 (market cap $349.77B). The key difference: Home Depot Inc is far larger — about 21.1× BridgeBio Pharma Inc's market cap, and Home Depot Inc pays a 2.66% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HD | |
|---|---|---|
Market Cap | $16.61B | $349.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $423.42 |
52-Week Low | $47.29 | $297.51 |
Enterprise Value | $18.16B | $411.32B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Home Depot (HD) trades at $354.48, down 0.32% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $368.75. Recent earnings showed mixed results, with Q1 2026 beating expectations but Q3 2025 missing, while revenue grew to $159.51B in 2025. The stock faces headwinds from weak big-ticket demand and rising mortgage rates, as noted in recent news, but benefits from strong Pro segment growth and housing market tailwinds.
The outlook remains cautiously optimistic, with upside potential from analyst targets and operational resilience, though risks include margin pressure and economic sensitivity. Investors should weigh solid fundamentals against near-term volatility in housing-related spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
